heart transplant News
-
CARMAT announces the first implant of its Aeson total artificial heart in The Netherlands
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces the first implant of theAeson artificial heart in The Netherlands. The implant procedure was performed by theHeart Team led ...
By Carmat
-
CARMAT announces the completion of its investigations on previously identified quality issues
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the completion of investigations on its prostheses. Following the occurrence of a quality issue affecting some of its prostheses, ...
By Carmat
-
Puzzle Medical to Present at TCT 2022 Its First-in-Human Study Results for the ModulHeart™
Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). PMD announced it will present its first-in-human results for the ModulHeartTM in the following session during the Transcatheter Cardiovascular Therapeutics (TCT) meeting held September 16-19, 2022 at the Boston Convention ...
-
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Following Significant Scientific Achievement
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, announced it has modified its Regulation A+ (Mini-IPO) offering following a successful September re-launch. BIOLIFE4D has raised more than $3M in equity crowdfunding investments since February of 2018. BIOLIFE4D’s modified Regulation A+ offering will allow the company to ...
By BIOLIFE4D
-
Carmat outlines commercial and development plan for its total artificial heart
Addressable market in the bridge-to-transplant indication of more than 2,000 patients a year in Europe Company prepares for commercial launch in Q2 2021, with initial focus on Germany and France Robust clinical plan to support adoption and sales development Virtual conference with Stéphane Piat today at 5 pm CET CARMAT (FR0010907956, ALCAR), the designer and developer of the ...
By Carmat
-
Puzzle Medical to Present at AHA 2022 its First-in-Human Study Results
Puzzle Medical Devices Inc. is delighted to announce its first-in-human results for the ModulHeart have been presented at the prestigious American Heart Association (AHA) meeting held November 5–7, 2022 at the McCormick Place Convention Center in Chicago, IL. Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function ...
-
Procyrion Named Most Innovative Heart Pump Technology In 2018 Global Healthcare and Pharmaceutical Awards
Houston medical device developer Procyrion Inc. today announced they have won the Most Innovative Heart Pump Technology award in the 2018 Global Healthcare and Pharmaceutical Awards for their device, Aortix™, a catheter-deployed circulatory support device designed initially to address cardiorenal syndrome in heart failure patients. The award celebrates the contributions made by ...
-
CARMAT announces a new commercial implant of its Aeson artificial heart at University Medical Center Schleswig-Holstein in Kiel, Germany
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its Aeson® bioprosthetic artificial heart in a commercial setting. This new commercial implant of the Aeson® device was ...
By Carmat
-
Procyrion, Inc. Wins Best Overall Medical Device Product in 2018 Medtech Breakthrough Awards
Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, today announced that its AortixTM device won the MedTech Breakthrough Award for "Best Overall Medical Device Product." MedTech Breakthrough is an independent organization that recognizes the top companies, technologies and products in the global health and medical ...
-
Berlin Heart Enrolls First Patients in Clinical Study to Investigate Innovative Mobilization Option for Children Waiting for a Heart Transplantation
Berlin Heart is pleased to announce that the first patients are enrolled in the "E-MOTION" study: “The use of the EXCOR® Active driving unit for MObilizaTION of pediatric patients with Ventricular Assist Device support”. This observational, international, multi-center study investigates the improved mobility, patient outcome and the impact of the mobile driving concept ...
-
Berlin Heart Today Announces CE Approval and First Implantation of an Innovative Bridging Solution for Single Ventricle Patients
Berlin, March 2021: With the first-in-man implantation of the Berlin Heart Venous Cannula at the LMU University Hospital Munich (Grosshadern), Germany, Berlin Heart offers patients with a failing Fontan circulation a unique chance to survive the waiting time for a donor heart. These patients are in a life-threatening condition: their health has deteriorated so much that they desperately need a ...
-
BIOLIFE4D Becomes First U.S. Company to Successfully Demonstrate Ability to 3D Bioprint a Mini Human Heart
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully demonstrated its ability to 3D bioprint a mini human heart, a significant step toward its goal of producing a full-sized human heart viable for transplant. The scientific milestone was accomplished at the Company’s research facility at ...
By BIOLIFE4D
-
Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart
Montreal-based Puzzle Medical Devices Inc., announced today the successful completion of the company’s ?rst-in-human study to evaluate the performance of its ModulHeart percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure (HF). Four patients had ModulHeart deployed to provide circulatory support while undergoing ...
-
UPS manager in Omaha Honored for outstanding community service
UPS (NYSE: UPS) has awarded Terry Brown of Omaha, Neb., the Jim Casey Community Service Award, the company's top honor worldwide for community service. Brown, a UPS human resources manager, was recognized for his long-standing commitment to service in the Omaha community, where he donates more than 60 hours a month of volunteer service to local non-profits. Brown's dedication to service began ...
-
Medical Device Company Procyrion, Inc. Hires Three to Support Growth; Continues to Build
Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, announced today it has hired three additional team members to support the advancement of its intra-aortic heart pump, AortixTM, for use in NYHA Class III-IV heart failure patients. Patricia DaSilva, Margo Fendrich, and Aaron Stone will focus on product development and ...
-
BIOLIFE4D Names Pharmaceutical Veteran Kate Lewis as President
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Kate Lewis as President of the company. She joined BIOLIFE4D full time in early 2019 in a market and business development role before being elevated as the first female executive in Company history. Lewis brings more than 25 years of experience and ...
By BIOLIFE4D
-
Procyrion Raises $30 Million Series D to Support Clinical Trials of Its Aortix™ Percutaneous Blood Pump for Treating Heart Failure Patients
Procyrion, Inc., a clinical-stage medical device company, today announced the completion of a $30 million Series D funding round led by a new investor, Bluebird Ventures. Returning investors include Fannin Partners, Scientific Health Development, the State of Texas, and an undisclosed strategic investor. The company is developing its Aortix™ system, a percutaneous blood pump initially ...
-
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardiac Stress, Injury, Structure, and Function at Month 12 – – Treatment with Patisiran Demonstrated Generally ...
-
Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch Ventricular Restoration System
Santa Clara, Calif.– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the AccuCinch® Ventricular Restoration System. Currently being evaluated in the CORCINCH-HF pivotal clinical trial, the AccuCinch System ...
-
Endotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the U.S. Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal Investigational Device Exemption (IDE) trial investigating the Cordella Pulmonary Artery (PA) Pressure Sensor1, shifting ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you